scholarly journals FIRST‐LINE IBRUTINIB + VENETOCLAX TREATMENT FOR MANTLE CELL LYMPHOMA IN OLDER PATIENTS OR THOSE WITH TP53 MUTATION: A NEW OPEN‐LABEL ARM OF THE PHASE 3 PCYC‐1143 SYMPATICO STUDY

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
W. Jurczak ◽  
C. Tam ◽  
K. Eckert ◽  
J. Lin ◽  
J. K. Neuenburg ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Older Patients ◽  
Tp53 Mutation ◽  
Cell Lymphoma ◽  
First Line ◽  
Open Label ◽  
Phase 3 ◽  
Mantle Cell

scholarly journals A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma

Haematologica ◽  
2018 ◽  
Vol 104 (1) ◽  
pp. 138-146 ◽  
Author(s):  
Rémy Gressin ◽  
Nicolas Daguindau ◽  
Adrian Tempescul ◽  
Anne Moreau ◽  
Sylvain Carras ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Older Patients ◽  
Cell Lymphoma ◽  
Line Treatment ◽  
Phase 2 ◽  
First Line ◽  
Phase 2 Study ◽  
Mantle Cell ◽  
First Line Treatment

MCL-129: First-Line Ibrutinib Plus Venetoclax in MCL for Older Patients or Those with a TP53 Mutation: Ongoing Open-Label Arm of the PCYC-1143 Phase 3 SYMPATICO Study

2020 ◽  
Vol 20 ◽  
pp. S259
Author(s):  
Michael L. Wang ◽  
Wojciech Jurczak ◽  
Karl Eckert ◽  
Jennifer Lin ◽  
Jutta Neuenburg ◽  
...  
Keyword(s):  
Older Patients ◽  
Tp53 Mutation ◽  
First Line ◽  
Open Label ◽  
Phase 3

scholarly journals Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

The Lancet ◽  
2016 ◽  
Vol 387 (10020) ◽  
pp. 770-778 ◽  
Author(s):  
Martin Dreyling ◽  
Wojciech Jurczak ◽  
Mats Jerkeman ◽  
Rodrigo Santucci Silva ◽  
Chiara Rusconi ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Open Label ◽  
Phase 3 ◽  
Mantle Cell ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document